Quidel Corporation (NASDAQ:QDEL) headquartered in San Diego, will host a conference call for the investment community to discuss the 3Q20 financial results on 29th October 2020 at 5:00 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.quidel.com
Earnings Expectation
Quidel Corporation is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, QDEL is expected to report 3Q20 income of $ 4.75 per share from revenue of $ 450.39 million. For the full year, analysts anticipate top line of $ 1519.15 million, while looking forward to income of $ 15.73 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 475.00 million ~ $ 477.00 million
Click Here For More Historical Outlooks Of Quidel Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, womens and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine.
